SystImmune

Beyond's analysis on SystImmune

• 2026-09-12 — SystImmune’s Phase 1 data for Iza-bren show promising activity in EGFR‑mutated lung cancer, backing a 2.5 mg/kg dose for Phase 3

Recent news mentioning SystImmune

• 2026-09-12 — SystImmune, Inc. to Present New Global Data on Iza-bren (izalontamab brengitecan) in EGFR-mutated Non-Small Cell Lung Cancer at WCLC Congress 2026
• 2026-08-05 — SystImmune Announces First Patient Dosed in Global Phase 3 Trial of BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer

Appears alongside

• WCLC

Browse the full archive →